Product details
GHRP-6 is a synthetic hexapeptide GHSR agonist within the GHRP family, distinguishable from its siblings (GHRP-2, Ipamorelin, Hexarelin) by its particular feature of producing robust appetite stimulation in addition to GH release. The appetite effect comes from GHRP-6's ghrelin-pathway activation at the hypothalamic-arcuate nucleus level, ghrelin is the endogenous appetite-stimulating hormone, and GHSR agonists at higher doses recapitulate part of ghrelin's appetite-driving activity. In research contexts, GHRP-6 is studied both for GH-release pharmacology and for orexigenic (appetite-stimulating) applications, making it the GHRP-family member most relevant to research workflows that want both effects rather than just one.
Peptuno supplies GHRP-6 as a lyophilized powder at ≥99.0% HPLC purity. The hexapeptide is straightforward to synthesize and the analytical packet covers peak-integration HPLC plus mass spec. Two standard fill sizes (5 mg and 10 mg) cover typical research workflows. For research workflows specifically studying appetite-pharmacology, GHRP-6 is the most appropriate member of the GHRP family; for cleaner GH-selective work, Ipamorelin is preferred to avoid the appetite-and-cortisol confounders.
FAQ
- What distinguishes GHRP-6 from GHRP-2 and Ipamorelin within the GHRP family?
- GHRP-6's defining feature among GHSR agonists is its substantial appetite-stimulating effect, at typical research doses, GHRP-6 produces measurable orexigenic activity that GHRP-2 (smaller appetite effect) and Ipamorelin (essentially no appetite effect) lack. The appetite stimulation comes from GHRP-6's binding profile at the hypothalamic-arcuate-nucleus GHSR, which is the same receptor that endogenous ghrelin engages to drive hunger signaling. The trade-off is a less GH-selective pharmacological profile compared to Ipamorelin. For research workflows specifically studying appetite pharmacology, GHRP-6 is the most appropriate GHRP-family choice; for clean GH-selective work, Ipamorelin remains the preferred tool.
- How is GHRP-6 reconstituted and stored for research workflows?
- Lyophilized GHRP-6 reconstitutes cleanly in bacteriostatic water for injection (BWFI) for multi-use research stocks or sterile water for injection (SWFI) for single-use preparations. The hexapeptide dissolves within 30-60 seconds with gentle swirl; do not vortex (the foaming entrains air and accelerates surface-mediated aggregation). The reconstituted solution should be aliquoted into single-use volumes immediately and held at -20 °C with strict freeze-thaw management, as with the rest of the GHRP family, freeze-thaw cycling is the dominant in-lab degradation pathway, not slow temperature drift. Working stocks are typically prepared at 1-5 mg/mL; for in vivo administration the working concentration is further diluted to the protocol-specified dose volume.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.